Plasma Translocator Protein Levels and Prognosis of Large Hemispheric Infarct
Wei-Hung Chen, MD 1 , Hsu-Lin Yeh, MD 1 , Lin-Ming Lien, PhD 1, 2 , Chyi-Huey Bai, PhD 3 ,
1 Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital
2 School of Medicine, Taipei Medical University
3 School of Public Health, Taipei Medical University
Wei-Hung Chen , MD
Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital
Plasma translocator protein (TSPO) has been shown to be associated with poor functional outcome in acute ischemic stroke. Its relationship with different stroke subtypes has not been tested yet. This study was aimed to measure the level of TSPO in patients with large hemispheric infarct (LHI) and determine its association with the degree of stroke severity and its ability to predict functional outcomes.
MATERIAL and METHOD:
In total, 50 patients with LHI were enrolled. Demographic information, cerebral risk factors, and stroke severity were examined at the baseline. The National Institutes of Health Stroke Scale, modified Rankin Scale (mRS), and Barthel index (BI) were assessed at 3 months after stroke onset. Baseline fasting plasma TSPO levels were assessed within 24 h after the incident stroke and during hospitalization (on days 8~10). Lower and higher TSPO groups were divided based on the median value.
Baseline characteristics between the lower and higher TSPO groups showed no significant differences in age, gender, stroke severity, or clinical parameters. There are no differences in the proportion of patients with poor functional outcome (mRS≥4) or severe disability (BI of ≤30) between higher and lower TSPO groups. Patients with a poor functional outcome have a higher TSPO (0.831±0.428 vs. 0.583±0.414, p=0.044); while in patients with severe disability, TSPO levels show no significant difference (0.804±0.453 vs. 0.633±0.407, p=0.170).
In this study, plasma TSPO only weakly associates with poor prognosis of LHI. Further study with larger number of patients is necessary.